Treating and Managing MS with Kesimpta®▼
Novartis MS Meeting featuring
Dr. Wallace Brownlee, National Hospital for Neurology & Neurosurgery, London
Saturday 19th November 2022
▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.